Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0041-1726688
Anti-IgE Monoclonal Antibody in Allergic Bronchopulmonary Aspergillosis Not Responding to Systemic Steroids
![](https://www.thieme-connect.de/media/10.1055-s-00045654/202103/lookinside/thumbnails/10.1055-s-0041-1726688-1.jpg)
Abstract
Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity disorder caused by Aspergillus fumigatus commonly among patients of bronchial asthma. Early diagnosis is the key to successful management and preventing parenchymal destruction. Most of the patients respond well to systemic steroids. In patients not responding to standard treatment, the other treatment options include pulse steroids, antifungals, immunosuppressants, and omalizumab. But exact indication for each of these is not well established. Here we report a 41-year-old ABPA patient who was not responding to systemic steroids became totally asymptomatic with the administration of omalizumab.
Publication History
Article published online:
25 May 2021
© 2021. Nitte (Deemed to be University). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110 (05) 685-692
- 2 Hinson KFW, Moon AJ, Plummer NS. Broncho-pulmonary aspergillosis; a review and a report of eight new cases. Thorax 1952; 7 (04) 317-333
- 3 Greenberger PA. Clinical aspects of allergic bronchopulmonary aspergillosis. Front Biosci 2003; 8: s119-s127
- 4 Kumar R. Mild, moderate, and severe forms of allergic bronchopulmonary aspergillosis: a clinical and serologic evaluation. Chest 2003; 124 (03) 890-892
- 5 Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts M, Harris KE. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med 1977; 86 (04) 405-414
- 6 Schwartz HJ, Greenberger PA. The prevalence of allergic bronchopulmonary aspergillosis in patients with asthma, determined by serologic and radiologic criteria in patients at risk. J Lab Clin Med 1991; 117 (02) 138-142
- 7 Wark PA, Hensley MJ, Saltos N. et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol 2003; 111 (05) 952-957
- 8 Mulliez P, Croxo C, Roy-Saint Georges F, Darras A. Allergic broncho-pulmonary aspergillosis treated with voriconazole. Rev Mal Respir 2006; 23 (1 Pt 1) 93-94
- 9 Thomson JM, Wesley A, Byrnes CA, Nixon GM. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis. Pediatr Pulmonol 2006; 41 (02) 164-170
- 10 Laoudi Y, Paolini JB, Grimfed A, Just J. Nebulised corticosteroid and amphotericin B: an alternative treatment for ABPA?. Eur Respir J 2008; 31 (04) 908-909
- 11 Avila PC. Does anti-IgE therapy help in asthma? Efficacy and controversies. Annu Rev Med 2007; 58: 185-203
- 12 Infar D, Crameri R, Lamers R, Achatz G. Molecular and cellular targets of anti-IgE antibodies. Allergy 2005; 60 (08) 977-985
- 13 Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006; 354: 2689-2695
- 14 van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007; 62 (03) 276-277